Danger zones: choice of drugs

RENÉE, Aesthetic Service

RENÉE bionic fillers are monophasic gels based on hyaluronic acid from the bacterium Bacillus Subtilis (bacillus subtilis). RENÉE fillers are stabilized with a low BDDE content of 5-6% and enriched with amino acids such as proline and glycine, which are structural elements of the extracellular matrix. The visible result lasts 8-12 months. Fillers are distinguished by high plasticity, light and elastic structure, lack of migration in tissues, and a clinically proven safety and effectiveness profile. The new product booster RENEE PRIME is created for the thinnest and most delicate areas.

You can find out more detailed information about the drug from the official representative - the Aesthetic Service company.

Prostrolane, Flosal

Prostrolane is a line of new generation revitalizing preparations to solve the main aesthetic imperfections of the skin. A feature of the Prostrolane series peptide revitalizants is the presence of partial stabilization of hyaluronic acid, which significantly prolongs the work of the drugs in tissues, slowing down their degradation. The Prostrolane line includes three drugs.

Prostrolane Natural-B – revitalization with a filling effect. Designed to correct wrinkles of varying depths, unhealthy complexion, pronounced nasolacrimal groove, sagging and atony of the skin in the face, neck, décolleté and hands.

Prostrolane Blanc-B – melanoregulation with a filling effect. Designed for the correction of age spots of various origins and locations, “dark circles” around the eyes, photodamage to the skin in the décolleté area, sagging and atony of the skin of the face, neck, décolleté and hands.

Prostrolane Inner-B - liporeduction of local fat deposits with a lifting effect. Intended for correction of local fat deposits in the lower third of the face (“double chin”), fuzzy facial oval, hypertrophied nasolabial fat packets, local fat deposits in the area of the inner surfaces of the arms, thighs, abdomen, buttocks, and back.

All drugs in the line activate the processes of neocollagenesis and cellular regeneration, have a lifting effect, and slow down involutive processes due to the work of patented peptide complexes in the structure of HA.

You can find out more detailed information about the drug from the official representative - the Flosal company:

flosal.com.ua
Kyiv, Bolshaya Vasylkivska str. 28v
0-800-300-850
+380-67-622-17-09

Alexa Volume, Hyalual

Designed to fill deep soft tissue wrinkles and replenish lost volume associated with age-related changes, and is also used to lift eyebrows, correct the bridge of the nose and chin. The filler contains more than 90% pure, highly purified hyaluronic acid and the smallest amount of ineffective BDDE fractions, which causes less swelling, a short rehabilitation period, and less pain. Alexa Volume filler contains cross-linked hyaluronic acid 20 mg, sodium phosphate buffer pH 7.2. The minimum interval between two injection procedures is 14 days. The result is individual and depends on the physiological characteristics of the individual person’s body.

You can find out more detailed information about the drug from the official representative - the Hyalual company.

BOTOX®, Allergan

This block of information is intended for doctors only!

BOTOX® (botulinum toxin type A) is a prescription drug used for both aesthetic and therapeutic procedures – approved for 35 indications ^a,1 in approximately 97 countries worldwide ^b,2 .

For aesthetic indications, it is used for temporary correction of facial wrinkles ³ :

• moderately or severely expressed vertical wrinkles between the eyebrows, visible with maximum frowning (glabellar wrinkles or glabellar wrinkles);

• and/or deep lateral periorbital wrinkles (“crow’s feet”), visible with a maximally open smile;

• and/or moderate to severe forehead wrinkles visible at maximum brow elevation.

More than 100 million bottles of BOTOX® have been sold worldwide since 1995 ^b,c,4 . The safety and effectiveness of BOTOX® have been established in clinical studies involving more than 22,000 patients treated with BOTOX® ^d,5,6 .

190 clinical studies ^d.5 and 3800+ publications in peer-reviewed publications, including publications on clinical and preclinical studies of BOTOX® ^d.i.6

BOTOX® is the most popular brand among patients. ^g,7

a For aesthetic use only.

b For aesthetic use only.

c First licensed botulinum toxin type A.

d Medicinal and aesthetic use.

i Data published in Biopharm Clinical as of June 20, 2019 6 include only manufacturer-sponsored clinical studies.

g Based on an Allergan-sponsored study of 595 physicians, patients who preferred this brand were from France (17), Germany (30), UK (38), Spain (45), Italy (44), Russia (50), Turkey (67), Saudi Arabia (48), Australia (59), China (103), Canada (60) and Brazil (34). Medical professionals were asked which brand of botulinum toxin for the treatment of expression lines and age-related wrinkles patients were most interested in.

1. Allergan. Unpublished data.

2. Allergan. Unpublished data as of September 30, 2019.

3. Instructions for medical use of the drug BOTOX®, date of last revision 04/04/2019, manufacturer Allergan Pharmaceuticals (Ireland).

4. Allergan. Unpublished data. March 2019.

5. Unpublished data from Allergan Inc. BOTOX® compared to competitors - number of peer-reviewed articles compared to competitors. February 2020.

6. Allergan. Unpublished data. April 2019.

7. Allergan. Unpublished data. March 2019.

For more detailed information about the drug, please contact your official representative, Allergan.